• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Orgenesis touts early clinical promise of CAR-T therapy with decentralized production in mind

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Sep 03, 2024 at 11:22: AM
via As Orgenesis works to decentralize and democratize CAR-T therapies, its candidate therapy has shown complete response rates of more than 80% in a clinical study in China.

article source
 




Top Bottom
Back
Quote